Thymidylate synthase inhibitors

Update on Cancer Therapeutics

Volumn 1, Issue 4, 2006, Pages 403-427

  Ackland, Stephen P ^a,b,c   Clarke, Stephen J ^d   Beale, Phillip ^d   Peters, Godefridus J ^e  

^a NEWCASTLE MATER HOSPITAL   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Capecitabine; Dihydropyrimidine dehydrogenase; Fluoropyrimidines; Pemetrexed; Thymidylate synthase

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; 5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EMITEFUR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LEVAMISOLE; MITOMYCIN C; NAVELBINE; NOLATREXED; OXALIPLATIN; PEMETREXED; PEPTIDE DERIVATIVE; PLEVITREXED; RALTITREXED; TAXANE DERIVATIVE; TEGAFUR; THYMIDYLATE SYNTHASE INHIBITOR; UFT; VACCINE;

ANEMIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CELL CYCLE REGULATION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; DRUG ERUPTION; ENZYME INHIBITION; ENZYME REGULATION; FATIGUE; FEBRILE NEUTROPENIA; GENE CONTROL; HAND FOOT SYNDROME; HUMAN; LUNG CANCER; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33751252558     PISSN: 1872115X     EISSN: 1872115X     Source Type: Journal    
DOI: 10.1016/j.uct.2006.09.001     Document Type: Review

References (225)

1. Schmitz J.C., Liu J., Lin X., Chen T.M., Yan W., Tai N., et al. Translational regulation as a novel mechanism for the development of cellular drug resistance. Cancer Metastasis Rev 20 1-2 (2001) 33-41
2. Peters G.J., Backus H.H., Freemantle S., van Triest B., Codacci-Pisanelli G., van der Wilt C.L., et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587 2-3 (2002) 194-205
3. Kitchens M.E., Forsthoefel A.M., Rafique Z., Spencer H.T., and Berger F.G. Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation. J Biol Chem 274 18 (1999) 12544-12547
4. Pena M.M., Xing Y.Y., Koli S., and Berger F.G. Role of N-terminal residues in the ubiquitin-independent degradation of human thymidylate synthase. Biochem J 394 Pt 1 (2006) 355-363
5. Xi Y., Nakajima G., Schmitz J.C., Chu E., and Ju J. Multi-level gene expression profiles affected by thymidylate synthase and 5-FU in colon cancer. BMC Genom 7 1 (2006) 68
6. Schmitz J.C., Chen T.M., and Chu E. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res 64 4 (2004) 1431-1435
7. Yang Z., Cloud A., Hughes D., and Johnson L.F. Stable inhibition of human thymidylate synthase expression following retroviral introduction of an siRNA gene 12. Cancer Gene Ther 13 1 (2006) 107-114
8. Berg R.W., Ferguson P.J., Vincent M.D., and Koropatnick D.J. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Cancer Gene Ther 10 4 (2003) 278-286
9. Robinson H.M., Jones R., Walker M., Zachos G., Brown R., Cassidy J., et al. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene (2006)
10. Correale P., Del Vecchio M.T., Di Genova G., Savellini G.G., La Placa M., Terrosi C., et al. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 97 19 (2005) 1437-1445
11. Aschele C., Debernardis D., Tunesi G., Maley F., and Sobrero A. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and the relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6 (2000) 4797-4802
12. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55 7 (1995) 1407-1412
13. Johnston P.G., Benson A., Catalano P., Eapen S., Wolmark N., Sargent D., et al. The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: an Intergroup combined analysis. J Clin Oncol 23 16 Suppl. (2005) 3510 [meeting abstracts]
14. Kuramochi H., Hayashi K., Uchida K., Miyakura S., Shimizu D., Vallbohmer D., et al. 5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer (2006)
15. Westra J.L., Hollema H., Schaapveld M., Platteel I., Oien K.A., Keith W.N., et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 16 10 (2005) 1646-1653
16. Lenz H.J., Danenberg K.D., Leichman C.G., Florentine B., Johnston P.G., Groshen S., et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 4 5 (1998) 1227-1234
17. Lenz H.J., Leichman C.G., Danenberg K.D., Danenberg P.V., Groshen S., Cohen H., et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14 1 (1996) 176-182
18. Ahlgren J.D. Thymidylate synthase in nodal metastases: prognostic for chemosensitivity but not for adjuvant therapy?. J Clin Oncol 23 24 (2005) 5452-5454
19. Ohrling K., Edler D., Hallstrom M., Ragnhammar P., and Blomgren H. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information. J Clin Oncol 23 24 (2005) 5628-5634
20. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 3 (2004) 529-536
21. Smorenburg C.H., Peters G.J., van Groeningen C.J., Noordhuis P., Smid K., van Riel A.M., et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 17 1 (2006) 35-42
22. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 4 (2000) 1322-1327
23. Mauritz R., Schwabe W., Haeusler P., Noordhuis P., Smid K., McLeod H.L., et al. Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR. Nucleosides Nucleotides Nucleic Acids 23 8-9 (2004) 1471-1474
24. Paradiso A., Simone G., Petroni S., Leone B., Vallejo C., Lacava J., et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82 3 (2000) 560-567
25. Johnston P.G., Benson III A.B., Catalano P., Rao M.S., O'Dwyer P.J., and Allegra C.J. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 21 5 (2003) 815-819
26. Ichikawa W., Uetake H., Shirota Y., Yamada H., Nishi N., Nihei Z., et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9 2 (2003) 786-791
27. Ishikawa T., Sekiguchi F., Fukase Y., Sawada N., and Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58 4 (1998) 685-690
28. Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D.K., et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer 94 2 (2006) 281-286
29. Matsuyama R., Togo S., Shimizu D., Momiyama N., Ishikawa T., Ichikawa Y., et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer (2006)
30. Ochiai T., Nishimura K., Noguchi H., Kitajima M., Tsukada A., Watanabe E., et al. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 118 12 (2006) 3084-3088
31. Pullarkat S.T., Stoehlmacher J., Ghaderi V., Xiong Y.P., Ingles S.A., Sherrod A., et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1 1 (2001) 65-70
32. Lecomte T., Ferraz J.M., Zinzindohoue F., Loriot M.A., Tregouet D.A., Landi B., et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10 17 (2004) 5880-5888
33. Mandola M.V., Stoehlmacher J., Muller-Weeks S., Cesarone G., Yu M.C., Lenz H.J., et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63 11 (2003) 2898-2904
34. Kawakami K., and Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63 18 (2003) 6004-6007
35. Marcuello E., Altes A., del Rio E., Cesar A., Menoyo A., and Baiget M. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112 5 (2004) 733-737
36. Ulrich C.M., Bigler J., Velicer C.M., Greene E.A., Farin F.M., and Potter J.D. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9 12 (2000) 1381-1385
37. Mandola M.V., Stoehlmacher J., Zhang W., Groshen S., Yu M.C., Iqbal S., et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 5 (2004) 319-327
38. McLeod H.L., Sargent D., Marsh S., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5-FU)/CPT-11, 5-FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer. Proc Am Soc Clin Oncol 22 (2003) 52
39. Hitre E., Budai B., Adleff V., Czegledi F., Horvath Z., Gyergyay F., et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genom 15 10 (2005) 723-730
40. Alba E., Ribelles N., Sanchez A., Lopez Siles J., Sanchez M.J., Gonzalez E., et al. Pharmacogenetic study in patients (pts) with metastatic breast (MBC) and colorectal cancer (MCRC) treated with capecitabine (C). Eur J Cancer 3 2 (2005) 66
41. Ichikawa W., Uetake H., Shirota Y., Yamada H., Takahashi T., Nihei Z., et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89 8 (2003) 1486-1492
42. Uchida K., Hayashi K., Kuramochi H., and Takasaki K. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Int J Oncol 19 2 (2001) 341-346
43. Kornmann M., Schwabe W., Sander S., Kron M., Strater J., Polat S., et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9 11 (2003) 4116-4124
44. Etienne M.C., Chazal M., Laurent-Puig P., Magne N., Rosty C., Formento J.L., et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20 12 (2002) 2832-2843
45. Etienne M.C., Chatelut E., Pivot X., Lavit M., Pujol A., Canal P., et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 34 1 (1998) 92-97
46. Etienne M.-C., Lagrange J.L., Dassonville O., et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12 (1994) 2248-2253
47. Di Paolo A., Danesi R., Falcone A., Cionini L., Vannozzi F., Masi G., et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12 9 (2001) 1301-1306
48. Jiang H., Lu J., Jiang J., and Hu P. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol 44 11 (2004) 1260-1272
49. Mattison L.K., Ezzeldin H., Carpenter M., Modak A., Johnson M.R., and Diasio R.B. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 10 8 (2004) 2652-2658
50. Van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40 7 (2004) 939-950
51. Raida M., Schwabe W., Hausler P., Van Kuilenburg A.B.P., Van Gennip A.H., Behnke D., et al. Prevalence of a common point mutation in the Dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7 9 (2001) 2832-2839
52. Maring J.G., Van Kuilenburg A.B.P., Haasjes J., Piersma H., Groen H.J.M., Uges D.R.A., et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86 7 (2002) 1028-1033
53. Van Kuilenburg A.B.P., Meinsma R., Zoetekouw L., and Van Gennip A.H. High prevalence of the IVS14 + 1G > A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12 7 (2002) 555-558
54. Van Kuilenburg A.B.P., Haasjes J., Richel D.J., Zoetekouw L., Van Lenthe H., De Abreu R.A., et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6 12 (2000) 4705-4712
55. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 1 (1995) 111-113
56. Etienne M.C., Ilc K., Formento J.L., Laurent-Puig P., Formento P., Cheradame S., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br J Cancer 90 2 (2004) 526-534
57. Sohn K.J., Croxford R., Yates Z., Lucock M., and Kim Y.I. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96 2 (2004) 134-144
58. Cohen V., Panet-Raymond V., Sabbaghian N., Morin I., Batist G., and Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9 5 (2003) 1611-1615
59. Jakobsen A., Nielsen J.N., Gyldenkerne N., and Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23 7 (2005) 1365-1369
60. Etienne M.C., Formento J.L., Chazal M., Francoual M., Magne N., Formento P., et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14 12 (2004) 785-792
61. Sarbia M., Stahl M., von Weyhern C., Weirich G., and Puhringer-Oppermann F. The prognostic significance of genetic polymorphisms (methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, thymidilate synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer 94 2 (2006) 203-207
62. van Triest B., Pinedo H.M., Giaccone G., and Peters G.J. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11 4 (2000) 385-391
63. Noordhuis P., Holwerda U., van der Wilt C.L., van Groeningen C.J., Smid K., Meijer S., et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 15 7 (2004) 1025-1032
64. Ackland S.P., and Peters G.J. Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist Updat 2 4 (1999) 205-214
65. de Bruin M., Smid K., Laan A.C., Noordhuis P., Fukushima M., Hoekman K., et al. Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem Biophys Res Commun 301 3 (2003) 675-679
66. de Bruin M., van Capel T., Smid K., van der B.K., Fukushima M., Hoekman K., et al. Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate. Nucleosides Nucleotides Nucleic Acids 23 8-9 (2004) 1485-1490
67. Fanciullino R., Giacometti S., Aubert C., Fina F., Martin P.M., Piccerelle P., et al. Development of stealth liposome formulation of 2′-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. Pharm Res 22 12 (2005) 2051-2057
68. Saini A., Norman A.R., Cunningham D., Chau I., Hill M., Tait D., et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 88 12 (2003) 1859-1865
69. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 1 (2004) 23-30
70. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
71. Wolmark N., Wieand S., Kuebler J.P., Colangelo L., and Smith R.E. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J Clin Oncol 23 16 Suppl. (2005) LBA3500 [meeting abstracts]
72. Gill S., Loprinzi C.L., Sargent D.J., Thome S.D., Alberts S.R., Haller D.G., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 10 (2004) 1797-1806
73. Gray R.G., Barnwell J., Hills R., McConkey C., Williams N., Kerr D., et al. QUASAR: a randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. J Clin Oncol 22 14s (2004) 3501
74. Reigner B., Blesch K., and Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40 2 (2001) 85-104
75. Mader R.M., Schrolnberger C., Rizovski B., Brunner M., Wenzel C., Locker G., et al. Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer 88 5 (2003) 782-787
76. Reigner B., Verweij J., Dirix L., Cassidy J., Twelves C., Allman D., et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4 4 (1998) 941-948
77. Damle B., Ravandi F., Kaul S., Sonnichsen D., Ferreira I., Brooks D., et al. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 7 3 (2001) 517-523
78. Saif M.W. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer 5 3 (2005) 175-180
79. Camidge R., Reigner B., Cassidy J., Grange S., Abt M., Weidekamm E., et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol 23 21 (2005) 4719-4725
80. Shah H.R., Ledbetter L., Diasio R., and Saif M.W. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer 5 5 (2006) 354-358
81. Delord J.P., Pierga J.Y., Dieras V., Bertheault-Cvitkovic F., Turpin F.L., Lokiec F., et al. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda((R))) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer 92 5 (2005) 820-826
82. van Groeningen C.J., Peters G.J., Schornagel J.H., Gall H., Noordhuis P., de Vries M.J., et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18 14 (2000) 2772-2779
83. Peters G.J., Noordhuis P., Van Kuilenburg A.B.P., Schornagel J.H., Gall H., Turner S.L., et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol 52 1 (2003) 1-12
84. Fischel J.L., Formento P., Ciccolini J., Etienne-Grimaldi M.C., and Milano G. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs 15 10 (2004) 969-974
85. Ng M., Cunningham D., and Norman A.R. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 41 11 (2005) 1542-1546
86. van Cutsem E., Hoff P.M., Harper P., Bukowski R.M., Cunningham D., Dufour P., et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90 6 (2004) 1190-1197
87. Twelves C., Gollins S., Grieve R., and Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17 2 (2006) 239-245
88. Twelves C., Wong A., Nowacki M.P., Abt M., Burris III H., Carrato A., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 26 (2005) 2696-2704
89. Cassidy J., Douillard J.Y., Twelves C., McKendrick J.J., Scheithauer W., Bustova I., et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 94 8 (2006) 1122-1129
90. Cassidy J., Tabernero J., Twelves C., Brunet R., Butts C., Conroy T., et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22 11 (2004) 2084-2091
91. Bajetta E., Di Bartolomeo M., Mariani L., Cassata A., Artale S., Frustaci S., et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100 2 (2004) 279-287
92. Borner M.M., Bernhard J., Dietrich D., Popescu R., Wernli M., Saletti P., et al. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16 2 (2005) 282-288
93. Rea D.W., Nortier J.W., Bokkel Huinink W.W., Falk S., Richel D.J., Maughan T., et al. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16 7 (2005) 1123-1132
94. Cartwright T., Lopez T., Vukelja S.J., Encarnacion C., Boehm K.A., and Asmar L. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 5 1 (2005) 50-56
95. Bennouna J., Lledo G., Ychou M., Conroy T., Hebbar M., Adenis A., et al. Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). Eur J Cancer 3 Suppl. 2 (2005) 179
96. Feliu J., Salud A., Escudero P., Lopez-Gomez L., Bolanos M., Galan A., et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94 7 (2006) 969-975
97. Arkenau H.T., Kubicka S., Greil R., Schmoll H., Seufferlein T., Greaven U., et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metaststic colorectal carcinoma (MCRC): results of the safety and efficacy analysis. Eur J Cancer 3 Suppl. 2 (2005) 168
98. Glynne-Jones R., Dunst J., and Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?. Ann Oncol 17 3 (2006) 361-371
99. Glynne-Jones R., Sebag-Montefiore D., Maughan T.S., Falk S.J., and McDonald A.C. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 17 1 (2006) 50-56
100. De Paoli A., Chiara S., Luppi G., Friso M.L., Beretta G.D., Del Prete S., et al. Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. Ann Oncol 17 2 (2006) 246-251
101. Chau I., Brown G., Cunningham D., Tait D., Wotherspoon A., Norman A.R., et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24 4 (2006) 668-674
102. Kim J.S., Kim J.S., Cho M.J., Yoon W.H., and Song K.S. Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer. J Korean Med Sci 21 1 (2006) 52-57
103. Kim J.G., Sohn S.K., Kim D.H., Baek J.H., Jeon S.B., Chae Y.S., et al. Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 93 10 (2005) 1117-1121
104. Price T.J., Ross P.J., Hickish T., Tait D., Norman A.R., Ford H.E., et al. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 3 4 (2004) 235-242
105. Chong G., Dickson J.L., Cunningham D., Norman A.R., Rao S., Hill M.E., et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 93 5 (2005) 510-514
106. Rao S., Cunningham D., Price T., Hill M.E., Ross P.J., Tebbutt N., et al. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 91 5 (2004) 839-843
107. Kabbinavar F.F., Hambleton J., Mass R.D., Hurwitz H.I., Bergsland E., and Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 16 (2005) 3706-3712
108. Fernando N., Yu D., Morse M., Bolbe G., Odogwu L., Cruse J., et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. J Clin Oncol 23 16S (2005) 3556
109. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
110. Hochster H., Hart R.K., Ramanathan R.K., Hainsworth J., Griffing S., Mass R.D., et al. Safety, tolerability and efficacy of the addition of bevacizumab to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer (mCRC): results of TREE 2 cohort of the TREE study. Eur J Cancer 3 2 (2005) 173
111. Koizumi W., Saigenji K., Ujiie S., Terashima M., Sakata Y., and Taguchi T. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64 3 (2003) 232-236
112. Park Y.H., Ryoo B.Y., Choi S.J., and Kim H.T. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 90 7 (2004) 1329-1333
113. Giordano K.F., Jatoi A., Stella P.J., Foster N., Tschetter L.K., Alberts S.R., et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17 4 (2006) 652-656
114. Park Y.H., Kim B.S., Ryoo B.Y., and Yang S.H. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 94 7 (2006) 959-963
115. Morant R., Bernhard J., Dietrich D., Gillessen S., Bonomo M., Borner M., et al. Capecitabine in hormone-resistant metastatic prostatic carcinoma-a phase II trial. Br J Cancer 90 7 (2004) 1312-1317
116. Rodney A., Dieringer P., Mathew P., Jonasch E., Tannir N., and Pagliaro L.C. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 106 10 (2006) 2143-2147
117. Ghosn M., Chahine G., Kattan J., Farhat F., Nasr F., Moukadem W., et al. Vinorelbine (N)-capecitabine (C) combination in advanced breast cancer (ABC): long-term results of two multicentric phase II trials. J Clin Oncol 23 16 Suppl. (2005) 673 [meeting abstracts]
118. Nole F., Catania C., Sanna G., Imadalou K., Munzone E., Adamoli L., et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 17 2 (2006) 322-329
119. Davis A.J., Lewis C., Moylan E., Parnis F.X., and Ackland S.P. A phase II multicentre study of combination chemotherapy with capecitabine (C) and intravenous (Iv) vinorelbine (V) in patients (Pts) with pretreated metastatic breast cancer (Mbc). Asia Pacific J Clin Oncol 1 S1 (2005) A18
120. Delcambre C., Veyret C., Levy C., Switsers O., and Allouache D. A phase I/II study of capecitabine (X) combined with oral vinorelbine (N) as first- or second-line chemotherapy in patients (pts) with locally advanced or metastatic breast cancer (MBC). Eur J Cancer 3 Suppl. 2 (2005) 118
121. Sadahiro S., Suzuki T., Kameya T., Iwase H., Tajima T., and Makuuchi H. A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients. Cancer Chemother Pharmacol 47 5 (2001) 457-460
122. Ichikura T., Tomimatsu S., Okusa Y., Yahara T., Uefuji K., and Tamakuma S. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Cancer Chemother Pharmacol 38 5 (1996) 401-405
123. van Cutsem E., Findlay M., Osterwalder B., Kocha W., Dalley D., Pazdur R., et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18 6 (2000) 1337-1345
124. Nogue M., Salud A., Batiste-Alentorn E., Saigi E., Losa F., Cirera L., et al. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Eur J Cancer 41 15 (2005) 2241-2249
125. Lembersky B.C., Wieand H.S., Petrelli N.J., O'Connell M.J., Colangelo L.H., Smith R.E., et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24 13 (2006) 2059-2064
126. Hirata K., Horikoshi N., Aiba K., Okazaki M., Denno R., Sasaki K., et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5 8 (1999) 2000-2005
127. Ho D.H., Covington W., Brown N., Lin S.N., Pazdur R., Huo Y.Y., et al. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Cancer Chemother Pharmacol 46 5 (2000) 351-356
128. Ichikawa W., Takahashi T., Suto K., Yamashita T., Nihei Z., Shirota Y., et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer 91 7 (2004) 1245-1250
129. Takechi T., Fujioka A., Matsushima E., and Fukushima M. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38 9 (2002) 1271-1277
130. Fujiwara H., Terashima M., Irinoda T., Takagane A., Abe K., Nakaya T., et al. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 39 16 (2003) 2387-2394
131. Yamamoto S., and Kubota K. Level of 5-fluorodeoxyuridine 5′-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1, A preliminary study. J Exp Clin Cancer Res 24 3 (2005) 457-462
132. Yurimoto S., Miyakawa A., Okuzawa A., Sakamoto S., Sakamoto K., Hosoda S., et al. Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model. Anticancer Drugs 16 10 (2005) 1109-1114
133. Esmaeli B., Golio D., Lubecki L., and Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol 140 2 (2005) 325-327
134. Chu Q.S., Hammond L.A., Schwartz G., Ochoa L., Rha S.Y., Denis L., et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 10 15 (2004) 4913-4921
135. Sakata Y., Ohtsu A., Horikoshi N., Sugimachi K., Mitachi Y., and Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34 11 (1998) 1715-1720
136. Chollet P., Schoffski P., Weingang K., Schellens J., Pavlidis N., Droz J., et al. Phase II study with S-1 in patients with advanced gastric cancer. Proceeding of 11th NCI-EORTC-AACR meeting (2000)
137. Koizumi W., Kurihara M., Nakano S., Hasegawa K., and For the S-1 Cooperative Gastric Cancer Study Group. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58 3 (2000) 191-197
138. Koizumi W., Tanabe S., Saigenji K., Ohtsu A., Boku N., Nagashima F., et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89 12 (2003) 2207-2212
139. Ajani J.A., Lee F.C., Singh D.A., Haller D.G., Lenz H.J., Benson III A.B., et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24 4 (2006) 663-667
140. Tatsumi K., Yamauchi T., Kiyono K., Kishi K., Yanagihara Y., Imaoka T., et al. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase. J Biochem (Tokyo) 114 6 (1993) 912-918
141. Sugimachi K., and Maehara Y. A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer. Surg Today 30 12 (2000) 1067-1072
142. Nemunaitis J., Eager R., Twaddell T., Corey A., Sekar K., Tkaczuk K., et al. Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors. J Clin Oncol 18 19 (2000) 3423-3434
143. Jackman A.L., Theti D.S., and Gibbs D.D. Antifolates targeted specifically to the folate receptor. Adv Drug Deliv Rev 56 8 (2004) 1111-1125
144. Gibbs D.D., Theti D.S., Wood N., Green M., Raynaud F., Valenti M., et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. Cancer Res 65 24 (2005) 11721-11728
145. Hooijberg J.H., de Vries N.A., Kaspers G.J., Pieters R., Jansen G., and Peters G.J. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 58 1 (2005) 1-12
146. Hooijberg J.H., Broxterman H.J., Kool M., Assaraf Y.G., Peters G.J., Noordhuis P., et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59 11 (1999) 2532-2535
147. Kool M., van der L.M., de Haas M., Scheffer G.L., de Vree J.M., Smith A.J., et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96 12 (1999) 6914-6919
148. Wielinga P., Hooijberg J.H., Gunnarsdottir S., Kathmann I., Reid G., Zelcer N., et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 65 10 (2005) 4425-4430
149. Shafran A., Ifergan I., Bram E., Jansen G., Kathmann I., Peters G.J., et al. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res 65 18 (2005) 8414-8422
150. Rhee M.S., and Schneider E. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line. Biochem Pharmacol 69 1 (2005) 123-132
151. Bram E., Ifergan I., Shafran A., Berman B., Jansen G., and Assaraf Y.G. Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol (2006)
152. Clarke S.J., Jackman A.L., and Judson I.R. The history of the development and clinical use of CB 3717 and ICI D1694. Adv Exp Med Biol 339 (1993) 277-287
153. Jodrell D.I., Newell D.R., Morgan S.E., Clinton S., Bensted J.P., Hughes L.R., et al. The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. Br J Cancer 64 5 (1991) 833-838
154. Jackman A.L., Gibson W., Brown M., Kimbell R., and Boyle F.T. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol 339 (1993) 265-276 [review, 12 refs.]
155. Jodrell D.I., Newell D.R., Gibson W., Hughes L.R., and Calvert A.H. The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats. Cancer Chemother Pharmacol 28 5 (1991) 331-338
156. Jackman A.L., Boyle F.T., and Harrap K.R. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Invest New Drugs 14 3 (1996) 305-316
157. Clarke S.J., Hanwell J., de Boer M., Planting A., Verweij J., Walker M., et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 14 5 (1996) 1495-1503
158. Grem J.L., Sorensen J.M., Cullen E., Takimoto C.H., Steinberg S.M., Chen A.P., et al. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors. Clin Cancer Res 5 9 (1999) 2381-2391
159. Cunningham D., Zalcberg J., Maroun J., James R., Clarke S., Maughan T.S., et al. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. A review of phase II/III trials. Eur J Cancer 38 4 (2002) 478-486
160. Farrugia D.C., Aherne G.W., Brunton L., Clarke S.J., and Jackman A.L. Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies. Clin Cancer Res 6 9 (2000) 3646-3656
161. Cunningham D. Mature results from three large controlled studies with raltitrexed (Tomudex). Br J Cancer 77 2 (1998) 15-21
162. Maughan T.S., James R.D., Kerr D.J., Ledermann J.A., McArdle C., Seymour M.T., et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 359 9317 (2002) 1555-1563
163. Cascinu S., Graziano F., Ferrau F., Catalano V., Massacesi C., Santini D., et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 13 5 (2002) 716-720
164. Comella P., Casaretti R., De R., Avallone V., Izzo A., Fiore F., et al. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. Ann Oncol 13 12 (2002) 1874-1881
165. Laudani A., Gebbia V., Leonardi V., Savio G., Borsellino N., Cusimano M.P., et al. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. Anticancer Res 24 2C (2004) 1139-1142
166. Martoni A., Mini E., Pinto C., Gentile A.L., Nobili S., Dentico P., et al. Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study. Anticancer Res 23 1B (2003) 687-691
167. Neri B., Doni L., Fulignati C., Perfetto F., Turrini M., Andreoli F., et al. Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial. Anticancer Drugs 13 7 (2002) 719-724
168. Seitz J.F., Bennouna J., Paillot B., Gamelin E., Francois E., Conroy T., et al. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol 13 7 (2002) 1072-1079
169. Cortinovis D., Bajetta E., Di B.M., Dognini G., Beretta E., Ferrario E., et al. Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer. Tumori 90 2 (2004) 186-191
170. Santini D., Massacesi C., D'Angelillo R.M., Marcucci F., Campisi C., Vincenzi B., et al. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. Med Oncol 21 1 (2004) 59-66
171. Aparicio J., Vicent J.M., Maestu I., Bosch C., Galan A., Busquier I., et al. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study. Oncology 68 1 (2005) 58-63
172. Aparicio J., Vicent J.M., Maestu I., Garcera S., Busquier I., Bosch C., et al. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol 14 7 (2003) 1121-1125
173. Carnaghi C., Rimassa L., Garassino I., Zucali P.A., Masci G., Fallini M., et al. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol 13 9 (2002) 1424-1429
174. Feliu J., Salud A., Escudero P., Lopez-Gomez L., Pericay C., Castanon C., et al. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. Br J Cancer 90 8 (2004) 1502-1507
175. Feliu J., Castanon C., Salud A., Mel J.R., Escudero P., Pelegrin A., et al. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer 93 11 (2005) 1230-1235
176. Arends J.J., Sleeboom H.P., Leys M.B., Ten Bokkel H.D., de Jong R.S., Smit J.M., et al. A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. Br J Cancer 92 3 (2005) 445-448
177. Kralidis E., Aebi S., Friess H., Buchler M.W., and Borner M.M. Activity of raltitrexed and gemcitabine in advanced pancreatic cancer. Ann Oncol 14 4 (2003) 574-579
178. Van Laethem J.L., Van M.P., Verslype C., Polus M., Demols A., Houbiers G., et al. Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study. Oncology 67 5-6 (2004) 338-343
179. Baas P., Ardizzoni A., Grossi F., Nackaerts K., Numico G., Van Marck E., et al. The activity of raltitrexed (Tomudex(R)) in malignant pleural mesothelioma. an EORTC phase II study (08992). Eur J Cancer 39 3 (2003) 353-357
180. Fizazi K., Doubre H., Le Chevalier T., Riviere A., Viala J., Daniel C., et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21 2 (2003) 349-354
181. Porta C., Zimatore M., Bonomi L., Imarisio I., Paglino C., Sartore-Bianchi A., et al. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48 3 (2005) 429-434
182. Porta C. Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma. Cancer Treat Rev 32 3 (2006) 229-233
183. van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 28 (2005) 6881-6889
184. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57 6 (1997) 1116-1123
185. Niyikiza C., Baker S.D., Seitz D.E., Walling J.M., Nelson K., Rusthoven J.J., et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1 7 (2002) 545-552
186. Niyikiza C., Hanauske A.R., Rusthoven J.J., Calvert A.H., Allen R., Paoletti P., et al. Pemetrexed safety and dosing strategy. Semin Oncol 29 6 Suppl. 18 (2002) 24-29
187. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 14 (2003) 2636-2644
188. Ceresoli G.L., Zucali P.A., Favaretto A.G., Grossi F., Bidoli P., Del C.G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 9 (2006) 1443-1448
189. Hughes A., Calvert P., Azzabi A., Plummer R., Johnson R., Rusthoven J., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20 16 (2002) 3533-3544
190. Smit E.F., Mattson K., von P.J., Manegold C., Clarke S., and Postmus P.E. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 14 3 (2003) 455-460
191. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., de M.F., von P.J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 9 (2004) 1589-1597
192. Clarke S.J., Abratt R., Goedhals L., Boyer M.J., Millward M.J., and Ackland S.P. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 13 5 (2002) 737-741
193. Rusthoven J.J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 17 4 (1999) 1194
194. Scagliotti G.V. Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer. Semin Oncol 32 2 Suppl. 2 (2005) S5-S8
195. Scagliotti G.V., Kortsik C., Dark G.G., Price A., Manegold C., Rosell R., et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 11 2 Pt 1 (2005) 690-696
196. Clarke S.J., Boyer M.J., Millward M., Underhill C., Moylan E., Yip D., et al. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 49 3 (2005) 401-412
197. Ma C.X., Nair S., Thomas S., Mandrekar S.J., Nikcevich D.A., Rowland K.M., et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 23 25 (2005) 5929-5937
198. Socinski M.A. Pemetrexed (Alimta) in small cell lung cancer. Semin Oncol 32 2 Suppl. 2 (2005) S1-S4
199. Oettle H., Richards D., Ramanathan R.K., Van Laethem J.L., Peeters M., Fuchs M., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16 10 (2005) 1639-1645
200. Pivot X., Raymond E., Laguerre B., Degardin M., Cals L., Armand J.P., et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85 5 (2001) 649-655
201. Paz-Ares L., Ciruelos E., Garcia-Carbonero R., Castellano D., Lopez-Martin A., and Cortes-Funes H. Pemetrexed in bladder, head and neck, and cervical cancers. Semin Oncol 29 6 Suppl. 18 (2002) 69-75
202. Cripps C., Burnell M., Jolivet J., Batist G., Lofters W., Dancey J., et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group Study. Ann Oncol 10 10 (1999) 1175-1179
203. Atkins J.N., Jacobs S.A., Wieand H.S., Smith R.E., John W.J., Colangelo L.H., et al. Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clin Colorectal Cancer 5 3 (2005) 181-187
204. Hochster H., Kettner E., Kroning H., Becker K., Lordick F., Ramanathan R.K., et al. Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. Clin Colorectal Cancer 5 4 (2005) 257-262
205. O'Shaughnessy J.A., Clark R.S., Blum J.L., Mennel R.G., Snyder D., Ye Z., et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 6 2 (2005) 143-149
206. Smith I. Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. Oncology (Williston, Park) 18 13 Suppl. 8 (2004) 63-65
207. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D., Groshen S., and Lenz H.J. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17 1 (2002) 46-49
208. Marsh S., McKay J.A., Cassidy J., and McLeod H.L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19 2 (2001) 383-386
209. Morganti M., Ciantelli M., Giglioni B., Putignano A.L., Nobili S., Papi L., et al. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 41 14 (2005) 2176-2183
210. Iacopetta B., Grieu F., Joseph D., and Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85 6 (2001) 827-831
211. Villafranca E., Okruzhnov Y., Dominguez M.A., Garcia-Foncillas J., Azinovic I., Martinez E., et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19 6 (2001) 1779-1786
212. Ishida Y., Kawakami K., Tanaka Y., Kanehira E., Omura K., and Watanabe G. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 20 5 (2002) 2805-2809
213. Tsuji T., Hidaka S., Sawai T., Nakagoe T., Yano H., Haseba M., et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9 10 (2003) 3700-3704
214. Fernandez-Contreras M.E., Sanchez-Prudencio S., Sanchez-Hernandez J.J., Garcia de Paredes M.L., Gisbert J.P., Roda-Navarro P., et al. Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol 28 5 (2006) 1303-1310
215. Dotor E., Cuatrecases M., Martinez-Iniesta M., Navarro M., Vilardell F., Guino E., et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24 10 (2006) 1603-1611
216. Sobrero A.F. Scheduling of fluorouracil: a forget-me-not in the jungle of doublets. J Clin Oncol 22 1 (2004) 4-6
217. Poplin E.A., Benedetti J.K., Estes N., Haller D.G., Mayer R.J., Goldberg R.M., et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23 9 (2005) 1819-1825
218. van Cutsem E, Labianca R, Hossfeld D, Bodoky G, Roth A, Aranda E, et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). J Clin Oncol (Meeting Abstracts) 2005, Jun 01, LBA8.
219. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol (Meeting Abstracts) 2004, Jul 15, p. 1264.
220. Douillard J.Y., Hoff P.M., Skillings J.R., Eisenberg P., Davidson N., Harper P., et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 17 (2002) 3605-3616
221. Carmichael J., Popiela T., Radstone D., Falk S., Borner M., Oza A., et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20 17 (2002) 3617-3627
222. Nukaya H., Hirashima N., Tanaka Y., Endo M., Matsunaga S., Hasegawa I., et al. An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer. Gan To Kagaku Ryoho 32 10 (2005) 1421-1426
223. Elnakat H., and Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 56 (2004) 1067-1084
224. Jackman A.L., Theti D.S., and Gibbs D.D. Antifolates targeted specifically to the folate receptor. Adv Drug Deliv Rev 56 (2004) 1111-1125
225. Peters G.J., Noordhuis P., van Groeningen C.J., Giaccone G., Holwerda U., Voorn D., et al. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 10 12 (2004) 4072-4076